MAGE-A4ᶜ¹º³²T for Multi-Tumor

Study Number

This study will investigate the safety and tolerability of MAGE-A4ᶜ¹º³²T cell therapy in subjects who have the appropriate HLA-A2 tissue marker and whose urinary bladder, melanoma, head and neck, ovarian, non-small cell lung, esophageal, gastric, synovial sarcoma, or myxoid/round call liposarcoma (MRCLS) tumor has the MAGE-A4 protein expressed. This study will take a subject's T cells and give them a T cell receptor protein that recognizes and attacks the tumors.

Full Title

Phase 1 dose escalation, multi-tumor study to assess the safety, tolerability and antitumor activity of genetically engineered MAGE-A4c1032T in HLA-A2+ subjects with MAGE-A4 positive tumors (ADP-0044-001)

ClinicalTrials.Gov ID

To inquire about participating in these studies, call 1-800-ROSWELL (1-800-767-9355) or e-mail